Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PAXMEDICA, INC.

(PXMD)
SummaryNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PaxMedica Announces Positive Results from Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder

02/09/2021 | 09:00am EST

PaxMedica, Inc. announced positive topline data from its Phase 2 dose-ranging clinical trial evaluating PAX-101 (IV suramin), an investigational drug with a novel mechanism that the Company is developing as a potential treatment for the core symptoms of Autism Spectrum Disorder. With no FDA approved treatments available currently, PAX 101 has the potential to be the first drug approved for treatment of the core symptoms of ASD. The Phase 2 study was a dose-ranging, randomized, double-blind, placebo-controlled, multidose trial evaluating the safety and efficacy of PAX-101 in patients diagnosed with moderate to severe autism spectrum disorder. In the 14-week trial, patients were randomized 1:1:1 to receive 10mg/kg of PAX-101, 20mg/kg of PAX-101 or placebo infusions every 4 weeks. Infusions were administered at baseline, week 4 and week 8. There was a 6-week follow-up after the last dose of study medication. The trial enrolled 52 patients from 6 sites across South Africa. The study population included a patient population with diverse ethnicity and the mean age for the study population was 8.43 (± SD 3.24). Forty-three (43) subjects completed the study, with 5 withdrawals due to COVID-19 lockdowns, 1 for an adverse event, and 2 for other reasons.


ę S&P Capital IQ 2021
All news about PAXMEDICA, INC.
10/28Paxmedica, Inc. Presents Clinical Data and New Analyses from A Phase 2 Trial of Pax-101..
CI
08/19PaxMedica to Present Data from its Recent Phase 2 Trial of PAX-101 (IV suramin) in Chil..
CI
02/09PaxMedica Announces Positive Results from Phase 2 Trial of PAX-101 (IV suramin) in Chil..
CI
2020PaxMedica, Inc. announced that it has received $3 million in funding
CI
2020PaxMedica, Inc. announced that it expects to receive $3 million in funding
CI
2020PaxMedica, Inc. has filed an IPO in the amount of $18.4575 million.
CI
More news
Financials (USD)
Sales 2019 - - -
Net income 2019 -0,60 M - -
Net cash 2019 0,02 M - -
P/E ratio 2019 -
Yield 2019 -
Capitalization 59,1 M 59,1 M -
EV / Sales 2018 -
EV / Sales 2019 -
Nbr of Employees 3
Free-Float 26,3%
Income Statement Evolution
Managers and Directors
Joseph Lucchese Chief Financial Officer
Zachary Rome Chief Operating Officer & Director
Karen A. Dawes Independent Director
Paul Kevin Wotton Independent Director
Robert F. Apple Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PAXMEDICA, INC.0.00%59
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298